Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

MarketWatch was able to verify Zeng's claims via videos and was also able to order delivery of Ozempic to an address in China. The price was 798 yuan ($108) for a one-month supply that is injected ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...

Novo Nordisk shares jumped 5.02% during early deals. On Monday, American telehealth firm Hims & Hers said in its earnings ...

Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing ...

The lawsuit claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was ...

Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...